Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of NNC0519-0130 in Japanese and Non-Japanese Males
NCT05870670Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing NNC0519-0130 with Placebo (2 arms). Primary endpoint: Area Under the NNC0519-0130 Plasma Concentration-Time Curve. Started May 2023; status: completed.
02
Drugs
NNC0519-0130
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05870670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870670.